U.S. Markets closed

Agilent Boosts Market Share With FDA Nod to New Cancer Test

Zacks Equity Research
Cardiovascular Systems (CSII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Agilent Technologies A recently received approval from the Food and Drug Administration (FDA) for a cancer diagnostic, named PD-L1 IHC 28-8 pharmDx. The test will be used in cases of urothelial carcinoma (“UC”) and squamous cell carcinoma of the head and neck (“SCCHN”).

This is a new step in the company's efforts to expand in the growing cancer-diagnostic market.

The PDL1 IHC 28-8 pharmDx test has already been approved for melanoma as well as non-squamous, non-small-cell lung cancer (“NSCLC”). Now, it has been approved for UC and SCCHN patients too. The test enables physicians in the United States to identify UC and SCCHN patients, who still have disease progression on or after platinum-based chemotherapy and are most likely to benefit from treatment with Opdivo.

Opdivo is an immunotherapy developed by Bristol-Myers Squibb (BMS). PD-L1 IHC 28-8 pharmDx was developed in collaboration with Opdivo maker, BMS. Currently, this test has a lot more utility than any other PD-L1 assay in the U.S. market.

Agilent's Role in Healthcare

Currently, the healthcare sector is witnessing a revolution. Personalized medicine is taking the center stage as it could provide improved patient care and better manage costs by administering the most appropriate treatment to individuals. It has been found that not all treatments are suitable for those suffering from a specific disease as some require more specialized tests.

The advancements could have far-reaching effects on the entire healthcare system as personalized medicines considerably improve patient care while reducing medical bills.

Agilent has signed several collaborative agreements with pharma and biotech companies including Pfizer PFE, AstraZeneca AZN, Bristol-MyersSquibb, Merck & Co. MRK, Amgen and Eli Lilly to develop diagnostics using both immunohistochemical and genomic-based technologies for the better treatment of cancer.

Bottom Line

Agilent is an original equipment manufacturer (“OEM”) of a broad-based portfolio of test and measurement products serving multiple end markets. We remain positive on Agilent's broad-based portfolio and increased focus on segments with higher growth potential. Further, the company continues to introduce high-margin products.

According to a report from marketsandmarkets.com, the worldwide cancer diagnostics market may reach $13.1 billion by 2020 from $7.1 billion by 2015, driven by several technological advancements in diagnostic platforms. Moreover, the market has seen the advent of hybrid imaging instruments with enhanced accuracy, such as PET/CT and SPECT/CT. These advancements have taken the cancer-diagnostics market to new heights.

We believe the new assay will help Agilent to cash in on the fast-growing healthcare cancer-diagnostics segment.

4 Stocks to Watch after the Massive Equifax Hack

Cybersecurity stocks spiked on recent news of a data breach affecting 143 million Americans. But which stocks are the best buy candidates right now? And what does the future hold for the cybersecurity industry?

Equifax is just the most recent victim. Computer hacking and identity theft are more common than ever. Zacks has just released Cybersecurity! An Investor’s Guide to inform Zacks.com readers about this $170 billion/year space. More importantly, it highlights 4 cybersecurity picks with strong profit potential.

Get the new Investing Guide now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Astrazeneca PLC (AZN) : Free Stock Analysis Report
 
Pfizer, Inc. (PFE) : Free Stock Analysis Report
 
Merck & Company, Inc. (MRK) : Free Stock Analysis Report
 
Agilent Technologies, Inc. (A) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

  • United Parcel Service Stock ahead of Q3 Earnings
    Finance
    Market Realist

    United Parcel Service Stock ahead of Q3 Earnings

    Will United Parcel Service’s Q3 Earnings Surprise the Market? United Parcel Service’s Q3 earnings United Parcel Service (UPS), the world’s premier express delivery giant, is set to announce its third-quarter earnings on October 24. It says it will issue

  • Tesla Stock Is Up 10.2%: What’s Helping It Defy Gravity?
    Finance
    Market Realist

    Tesla Stock Is Up 10.2%: What’s Helping It Defy Gravity?

    Tesla (TSLA) stock appears to be defying gravity today and is rallying despite the broader market sell-off. Today at 1:08 PM EDT, Tesla stock was up 10.2% from the previous session’s closing price. Earlier today, Citron Research—one of the Tesla bears—surprised the market by turning positive on TSLA for the first time.

  • A huge Amazon warehouse Prime Day outage may have been caused by moving off Oracle's databases
    Business
    Business Insider

    A huge Amazon warehouse Prime Day outage may have been caused by moving off Oracle's databases

    On Prime Day, Amazon's website crashed, while one of its biggest warehouses also experienced a technical outage that delayed thousands of package deliveries. According to documents obtained by CNBC, the outage was caused by Amazon moving its database for an Ohio warehouse off of Oracle's to its own. Amazon is planning to move completely off Oracle's database by 2020, but Oracle thinks it's a long shot.

  • 2 More Marijuana Stocks Are Moving to the NYSE
    Business
    Motley Fool

    2 More Marijuana Stocks Are Moving to the NYSE

    This year, we've witnessed GW Pharmaceuticals gain approval in the U.S. for the first cannabis-derived drug, and we watched as Vermont legalized recreational marijuana use entirely through the legislative process. This began with Cronos Group at the end of February, when it chose to list its shares on the Nasdaq. It was followed just a few months later by Canopy Growth Corp., which became the first marijuana stock to list on the NYSE.

  • Why Investors Are Paying a Premium for These 3 Biotech Stocks
    Business
    Motley Fool

    Why Investors Are Paying a Premium for These 3 Biotech Stocks

    Amarin stock exploded in September because it looks like Vascepa will become the next go-to drug for this enormous population. During the 8,179-patient Reduce-It trial, patients given Vascepa in addition to their normal statin treatments were 25% less likely to suffer a major cardiovascular event such as a heart attack. Over the past year, Amarin Corporation actually lost $92 million because sales of Vascepa just haven't kept pace with operating expenses.

  • Companies Say They're Ready to Move Supply Chains From China
    Finance
    Bloomberg

    Companies Say They're Ready to Move Supply Chains From China

    U.S. President Donald Trump imposed a 10 percent tariff on $200 billion of Chinese imports in September -- following an earlier round of tariffs on $50 billion of goods -- and promised to raise the duty to 25 percent in January. "We’re pro-actively taking action," Todd Bluedorn, chief executive officer of the Texas-based HVAC company, told analysts during an Oct. 22 earnings call.

  • MARKETS: Here's why stocks are selling off right now and what a bottom would look like
    Business
    Yahoo Finance Video

    MARKETS: Here's why stocks are selling off right now and what a bottom would look like

    Live from the floor of the New York Stock Exchange, Yahoo Finance's Jared Blikre joins Seana Smith to discuss the latest market moves.

  • 5 Deeply Discounted Value Stocks That Haven't Been This Cheap in at Least a Decade
    Business
    Motley Fool

    5 Deeply Discounted Value Stocks That Haven't Been This Cheap in at Least a Decade

    October has been a wake-up call for investors that the stock market won't go up in a straight line, even if we'd like it to. Sure, Bank of America (NYSE: BAC) has seen its stock catapult higher from its Great Recession lows, but its forward P/E of 9.8 would represent a more-than-decade low for the stock.

  • Finance
    CNBC

    Here's the tax bite on $1.6 billion Mega Millions and $620 million Powerball jackpots

    Strategies can be employed to reduce the amount of your win that is taxed, although they are best explored with the help of an experienced tax advisor. While it's anyone's guess who will end up winning the Mega Millions and Powerball jackpots, there's at least one guaranteed recipient of a chunk of the loot — the IRS. With the Mega Millions jackpot at $1.6 billion and Powerball's top prize at $620 million, that tax bill will be hefty even if the winner employs strategies to reduce their taxable income.

  • Suze Orman missed the point of retirement, and that’s why she went back to work
    News
    MarketWatch

    Suze Orman missed the point of retirement, and that’s why she went back to work

    Suze Orman did a smackdown of the FIRE (Financial Independence/Retire Early) movement on Paula Pant’s podcast. Coach Carson posted a balanced, informative response, appreciating Suze’s admonition to be sure you have enough for a risk-free retirement. Suze enumerated a string “what can go wrong” scenarios as evidence that early retirement (on less than $10 million) leaves you vulnerable when life hands you lemons — a whole tree of lemons.

  • The stock market's 'dead cat bounce' is over and the rolling bear market is making a comeback, Morgan Stanley says
    Business
    Business Insider

    The stock market's 'dead cat bounce' is over and the rolling bear market is making a comeback, Morgan Stanley says

    The stock market may have bounced back from its sharp sell-off at the beginning of October, but Morgan Stanley says the selling will pick back up soon. The firm expects the S&P 500 to slide back below the 200-day moving average, a key technical level. Tread carefully in tech and consumer discretionary, Morgan Stanley warns.

  • Business
    Motley Fool

    Parsing Visa's Big Quarterly Dividend Hike

    The ubiquitous financial services player Visa (NYSE: V) isn't exactly an income stock -- its dividend yield has fairly consistently been below 1% for years. Which raises two interesting questions for MarketFoolery host Chris Hill and senior analyst Jason Moser. In this segment from MarketFoolery, they discuss Visa's cash cow structure, its stock repurchases, and the M&A possibilities it thus far seems to be ignoring.

  • These stocks may be sacrificed in a cold war with China
    COL
    CNBC Videos

    These stocks may be sacrificed in a cold war with China

    Jim Cramer says the escalation in the United States' trade war with China could end in an outright cold war that debilitates parts of the stock market.

  • Is the New Energy Transfer LP a Buy?
    Finance
    Motley Fool

    Is the New Energy Transfer LP a Buy?

    Last week, Energy Transfer LP (NYSE: ET) emerged on the scene after the former Energy Transfer Equity completed the acquisition of its affiliate Energy Transfer Partners in a unit-for-unit exchange that simplified this complex midstream franchise. The transaction also created a much stronger company that has the financial resources to fund a significant slate of expansion projects. The new Energy Transfer is a behemoth in the midstream sector.

  • These community banks are saving hundreds of thousands of dollars a quarter following Trump's tax cuts
    Finance
    American City Business Journals

    These community banks are saving hundreds of thousands of dollars a quarter following Trump's tax cuts

    TrustCo Bank and Arrow Financial saw net income increase by more than 20 percent in the third quarter of 2018, as both banks saw profits from the Trump administration's tax cuts. One of the biggest changes from President Donald Trump's $1.5 billion tax overhaul lowers the corporate tax rate to 21 percent from 35 percent. It also eliminates the corporate alternative minimum tax.

  • News
    CNBC

    Here's how much money you should have saved by 50

    Fidelity, the nation's largest retirement-plan provider, recommends having the equivalent of six times your annual salary saved. To get to that number, Fidelity recommends saving 15 percent of your annual income. Make sure to invest these funds instead of leaving them in a traditional low-interest savings account.

  • Business
    Barrons.com

    Micron Technology Is Under the Gun as Demand Outlook Worsens

    The price of (MU) stock has fallen nearly 40% since the summer, but the upside has diminished as well, according to Susquehanna analyst Mehdi Hosseini. “Recent checks imply incremental weakness in Cloud and Enterprise spending expectations” for the first half of 2019, Hosseini wrote on Tuesday. Hosseini lowered his price target for Micron to $45 from $75, implying upside of about 17% from the current level.

  • Why Nektar Therapeutics Crashed 17.2% Today
    Business
    Motley Fool

    Why Nektar Therapeutics Crashed 17.2% Today

    After delivering a disappointing update on NKTR-214 in cancer patients this summer, Nektar Therapeutics' (NASDAQ: NKTR) shares have been struggling. The company didn't report any news today, so a negative report issued by Plainview LLC this month may be to blamed for its 17.2% tumble today. In February, Bristol-Myers Squibb (NYSE: BMY) inked a blockbuster deal to license rights to NKTR-214 following positive data last year for NKTR-214's use alongside Bristol-Myers' Opdivo.

  • Trump’s Tax Push to Help Middle Class Could Help Top Earners Too
    Politics
    Bloomberg

    Trump’s Tax Push to Help Middle Class Could Help Top Earners Too

    It’s still unclear how Trump will propose to reduce the tax burden on middle-class Americans, but one of the most straightforward ways would be to lower rates by 10 percent for single filers making up to $82,500. U.S. income tax rates are graduated and income dollars get taxed in chunks as they move up through the brackets -- which means wealthy Americans would also get to apply the reduced rate on their first dollars of income. “A millionaire gets the same size tax cut,” said Kyle Pomerleau, an economist at the conservative Tax Foundation.

  • Why These 3 Top Marijuana Stocks Slumped Today
    Business
    Motley Fool

    Why These 3 Top Marijuana Stocks Slumped Today

    With earnings season hitting a crescendo this week, investors are looking closely at the specific prospects for certain corners of the market, and that's contributing to disparities among the various major benchmarks followed most often by investors. Amid the crosscurrents, marijuana stocks took particularly hard hits, and New Age Beverages (NASDAQ: NBEV), Tilray (NASDAQ: TLRY), and Canopy Growth (NYSE: CGC) were among the worst performers on the day. All three of these stocks have given back some of their gains following the long-awaited legalization of recreational cannabis in the Canadian market last week. In the month leading up to the Oct. 17 start date for legal cannabis sales, New Age Beverages tripled in value, while Tilray had more than doubled since the end of August, and Canopy Growth had seen more modest gains of between 10% and 20%.

  • Dow tumbles nearly 550 points at lows amid corporate outlook, China selloff
    News
    MarketWatch

    Dow tumbles nearly 550 points at lows amid corporate outlook, China selloff

    It was a punishing start for stocks Tuesday as investors reacted negatively to quarterly results from a handful of blue chips and the cessation of a two-day rebound for China’s embattled stock market, reviving fresh questions about global economic growth prospects. The Dow Jones Industrial Average (DJIA) 548.62 points at its low and remained was recently 460 points, or 1.8%, at 24,862. The S&P 500 (SPX) fell 55 points, or 2%, to 2,696, retreating below a psychological and technical mark at 2,700, while the Nasdaq Composite Index (COMP) slid gave up 177 points, or 2.4%, to 7,291.

  • What to Expect from Bristol-Myers Squibb’s Q3 Earnings
    Finance
    Market Realist

    What to Expect from Bristol-Myers Squibb’s Q3 Earnings

    Bristol-Myers Squibb (BMY) is expected to report its third-quarter earnings on October 25. Analysts expect Bristol-Myers Squibb’s revenues to increase 8.87% from $5.25 billion in the third quarter of 2017 to $5.72 billion in the third quarte of 2018. In the last four quarters, Bristol-Myers Squibb’s revenue growth has been 3.93%–10.89%.

  • What Energy Transfer’s Technical Indicators Suggest
    Finance
    Market Realist

    What Energy Transfer’s Technical Indicators Suggest

    How Energy Transfer Stock Has Fared (Continued from Prior Part) Moving averages Let’s see where Energy Transfer (ET) stock might go from here. Energy Transfer stock is currently trading at $16.47, almost 6% and 3% below its 50-day and 200-day moving

  • Are AMD Investors Overreacting to Intel’s CPU Supply Update?
    Finance
    Market Realist

    Are AMD Investors Overreacting to Intel’s CPU Supply Update?

    Are AMD Investors Overreacting to Intel’s News? (Continued from Prior Part) The 2018 CPU story of AMD and Intel The Advanced Micro Devices-Intel CPU (central processing unit) story is taking an interesting twist in 2018 as Intel faces CPU supply shortage

  • 4 Things Aurora Cannabis Did Right Before Its NYSE Debut
    Business
    Motley Fool

    4 Things Aurora Cannabis Did Right Before Its NYSE Debut

    Aurora Cannabis (NASDAQOTH: ACBFF) (TSX: ACB) has sought to make it even easier for U.S. investors to buy its shares by arranging to have its shares listed on the New York Stock Exchange. Beginning tomorrow, Oct. 23, Aurora will join the elite group of cannabis companies whose shares trade on major U.S. exchanges. Getting ready for the increased exposure that a NYSE listing brings takes time and effort, and Aurora Cannabis hasn't wasted any time.